Mark Awad

Mark Awad is a thoracic oncologist and translational researcher who has led clinical and laboratory investigations of next-generation checkpoint targets including TIGIT, LAG-3, and TIM-3 in non-small cell lung cancer. His laboratory has dissected the mechanisms of response and resistance to anti-TIGIT plus anti-PD-L1 combinations and the importance of Fc-mediated effector functions in checkpoint antibody activity. He has contributed to clinical trials of tiragolumab, domvanalimab, and other novel checkpoint agents. His work bridges deep immunology with clinical biomarker development for combination immunotherapy.